Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy

• Mieke van Schaik,
• Aiko P.J. de Vries,
• Frederike J. Bemelman,
• Ton J. Rabelink,
• Leendert A. Trouw,
• Cees van Kooten,
• Yoe Kie Onno Teng

Affiliations

Mieke van Schaik

Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

Aiko P.J. de Vries

Department of Nephrology and Leiden Transplant Center, Leiden University Medical Center, Leiden, The Netherlands

Frederike J. Bemelman

Department of Nephrology, Amsterdam University Medical Center, Amsterdam, The Netherlands

Ton J. Rabelink

Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

Leendert A. Trouw

Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

Cees van Kooten

Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

Yoe Kie Onno Teng

Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; Correspondence: Yoe Kie Onno Teng, Leiden University Medical Center, Department of Nephrology, 9600, 2300RC Leiden, The Netherlands.